Abstract 139P
Background
The management of anal squamous cell carcinoma (ASCC) has yet to benefit from the progress of precision medicine. The few prognostic factors assessed to date are insufficient to accurately predict clinical outcomes. Patients with tumor resistant to chemoradiation therapy, or those experiencing localized recurrence after treatment, are subject to abdominoperineal resection (APR), an invasive procedure that significantly impairs quality of life. Genomic analyses could identify new prognostic biomarkers and potential avenues for targeted therapies.
Methods
We assessed the prognostic and theragnostic value of pathogenic variants identified in 571 cancer-related genes in surgical samples collected from a multicentric retrospective French cohort of 158 ASCC patients who underwent APR.
Results
Alterations in PI3K/AKT/mTOR (43%), chromatin remodeling (48%), and Notch pathways (22%) were frequent in HPV-positive tumors, while HPV-negative tumors (11%) often had variants in cell cycle regulation and genome integrity maintenance genes, like TP53 (59%) and TERT promoter mutations (47%). In patients with HPV-positive tumors, KMT2C (16%) and PIK3CA exon 9/20 pathogenic variants (22%) were associated with poor overall survival (Hazard Ratio (HR)KMT2C = 2.54, 95%CI = 1.25-5.17, p-value = 0.010; HRPIK3CA = 2.43, 95%CI = 1.3-4.56, p-value = 0.006), and progression-free survival (HRKMT2C = 3.38, 95%CI = 1.83-6.26, p-value < 0.001; HRPIK3CA = 1.81, 95%CI = 1.06-3.08, p-value = 0.029) in multivariate analyses. Alterations with theragnostic value in another cancer type (e.g., PIK3CAH1047R or loss-of-function variants in homologous repair genes) were detected in 43% of tumors.
Conclusions
PIK3CA exon 9/20 and KMT2C pathogenic variants are independent prognostic factors in patients with HPV-positive ASCC treated by APR. Importantly, the high prevalence of alterations with potential theragnostic value strongly supports the use of genomic profiling to allow patient enrollment in precision medicine clinical trials.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondation de France, Société Nationale Française de Gastroentérologie, Ligue Contre le Cancer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract